Semaglutide controlled release - Mapi Pharma
Alternative Names: GLP-1 - Mapi Pharma; GLP-1 Depot; Semaglutide - Mapi PharmaLatest Information Update: 12 May 2026
At a glance
- Originator Mapi Pharma
- Class Antihyperglycaemics; Glucagon-like peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Diabetes mellitus
Most Recent Events
- 04 May 2026 Mapi Pharma plans a phase I/II trial for Diabetes mellitus (SC) in May 2026 (NCT07563699)
- 19 Oct 2022 Phase-II clinical trials in Diabetes mellitus in Israel (Parenteral) (Mapi Pharma pipeline, October 2022)
- 11 Nov 2021 Glucagon-like peptide controlled release - Mapi Pharma is available for licensing as of 11 Nov 2021. https://mapi-pharma.com/about/our-strategy/